CONCORD DRUGS
Back to Income Statement
|
CONCORD DRUGS Last 5 Year Consolidated Net Profit History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|
| Consolidated Net Profit | ₹0.34 Cr | ₹0.47 Cr | ₹0.99 Cr | ₹1.59 Cr |
What is the latest Consolidated Net Profit of CONCORD DRUGS ?
| Year | Consolidated Net Profit |
|---|---|
| Mar2025 | ₹0.34 Cr |
| Mar2024 | ₹0.47 Cr |
| Mar2023 | ₹0.99 Cr |
| Mar2022 | ₹1.59 Cr |
How is Consolidated Net Profit of CONCORD DRUGS Trending?
| Years | Consolidated Net Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹0.34 Cr | -28.81 | |
| Mar2024 | ₹0.47 Cr | -52.13 | |
| Mar2023 | ₹0.99 Cr | -38.14 | |
| Mar2022 | ₹1.59 Cr | - | |
Compare Consolidated Net Profit of peers of CONCORD DRUGS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CONCORD DRUGS | ₹94.0 Cr | 1.4% | -0.8% | 28.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹467,630.0 Cr | -0.1% | 0.5% | 14% | Stock Analytics | |
| DIVIS LABORATORIES | ₹218,972.0 Cr | -0.9% | 21.1% | 25.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹188,358.0 Cr | -1.3% | 1.1% | 32.7% | Stock Analytics | |
| CIPLA | ₹118,916.0 Cr | 0.2% | 2.1% | -5.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,824.0 Cr | 0.2% | -7.7% | -7.5% | Stock Analytics | |
CONCORD DRUGS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CONCORD DRUGS | 1.4% |
-0.8% |
28.5% |
| SENSEX | 0.5% |
2.6% |
-3.7% |
You may also like the below Video Courses